Wave Life Sciences stock crashes 50% after weak weight-loss drug results
Wave Life Sciences saw its stock price plummet by nearly 50% on Thursday, hitting a 52-week low. The sharp decline followed disappointing updates from the company's weight-loss drug trial, WVE-007, which failed to meet analyst expectations.
In December, Wave had reported promising early results for its drug. A single 240 mg dose of WVE-007 showed a 9.4% reduction in visceral fat, a 4.5% drop in total body fat, and a 3.2% increase in lean mass. These figures had raised hopes for the drug's potential in obesity treatment.
However, Thursday's data from the 400 mg dose painted a different picture. While visceral fat reduction remained at 5.0%, the improvements in total fat and lean mass were far weaker—just 0.7% and 0.2%, respectively. Analysts noted that these results fell short of expectations, particularly when compared to the earlier 240 mg findings. Wave executives explained that the weaker performance in the 400 mg group may have stemmed from the participants' healthier baseline body composition. The Phase 1 portion of the INLIGHT study included 32 individuals in the 240 mg cohort, though the total number across all Phase 1 groups remains undisclosed. Looking ahead, the company expects stronger outcomes in the Phase 2a multidose trial. This next stage will involve patients with higher BMIs and weight-related conditions, which Wave believes will lead to 'substantially larger effects.' A more critical assessment of WVE-007's obesity potential will come in the mid-stage trial, set to begin in Q2 2026.
The latest trial results have cast doubt on WVE-007's near-term prospects, triggering a steep drop in Wave's share price. The company now pins its hopes on the upcoming Phase 2a study, where a broader patient group may yield more encouraging data. Investors will likely watch closely as the next trial phase approaches in 2026.
